Hemolysis may occur during infusion of an ABO-incompatible HSC component if the recipient has isoagglutinins directed against donor red blood cells, or later as a result of the production by donor lymphocytes of isoagglutinins directed against recipient ABO-antigens. Peripheral blood stem cell (PBSC) components collected by apheresis contain few red cells but considerably greater numbers of lymphocytes than marrow. We reviewed the transplant courses of 158 recipients of marrow (n ‫؍‬ 90) or PBSC (n ‫؍‬ 68) from HLA-identical, ABO-incompatible sibling donors. No patient experienced immediate or delayed hemolysis attributable to the ABO incompatibility. Recipients of minor ABO-incompatible red cell-replete marrow required fewer red cell transfusions during the first week after transplantation than recipients of PBSC or marrows depleted of red cells; the red cell transfusion requirements for the following 3 weeks did not differ. The maximum level of bilirubin did not differ for patients classified by ABO incompatibility or source of HSC. The development of positive antiglobulin tests occurred for eight marrow recipients from a separate group of 22 patients (17 marrow, five PBSC) for whom this testing was performed. None of these patients developed overt hemolysis. These data indicate that hemolysis complicating ABO-incompatible transplantation is not common after either marrow or PBSC transplantation. Bone Marrow Transplantation (2000) 26, 749-757. Keywords: transplantation; hematopoietic stem cell; bone marrow; peripheral blood stem cell; ABO incompatibility; isoagglutinin Hematopoietic stem cell (HSC) components may be transplanted between red blood cell antigen-disparate donors and recipients without an increase in graft-versus-host disease (GVHD) or graft rejection.
ABO incompatibility is classified according to whether donor isoagglutinins, isoantigens, or both are incompatible with those of the recipient. Major incompatibility occurs when patients have antibodies directed against donor red blood cell antigens; minor incompatibility occurs when donor plasma contains antibodies directed against patient red cells. For some transplants, bidirectional ABO incompatibility may be present.
The immediate risk of major ABO-incompatible bone marrow transplants is the risk of hemolysis of large quantities of red cells contained in the inocula, a risk that is much lower for recipients of PBSC collected by apheresis because of the lower volume of red blood cells in these components. Delayed hemolysis of the infused red cells may occur for patients conditioned with plasma exchange if recipient isoagglutinins rebound after the apheresis procedures. 6 These patients may also experience delayed red cell recovery after transplantation because of persistent host isoagglutinins that suppress red cell hematopoiesis. [7] [8] [9] In contrast, patients receiving minor ABO-incompatible transplants do not face a risk of immediate hemolysis from the infusion of incompatible red blood cells, but may experience delayed hemolysis mediated by donor lymphocytes carried in the HSC component. [10] [11] [12] These viable 'passenger lymphocytes' are capable of producing adequate levels of isoagglutinins to result in hemolysis of recipient red blood cells 7-14 days after transplantation. This delayed hemolysis after minor ABO-incompatible HSC transplants can be severe and fatal.
The incidence of hemolysis after minor ABO-incompatible transplantation is not established and may relate to the post-transplant immunosuppression used to suppress GVHD. 11 It is also not clear if manipulation of the HSC component before infusion, such as T or B cell depletion, will alter the risk of this complication. However, authors of several recently published case reports of hemolysis occurring after minor or bidirectional ABO-incompatible PBSC transplantation suggest that these recipients are at greater risk of this complication than are marrow recipients, and that the occurrence and severity of the hemolysis may be explained by the much greater number of lymphocytes contained in the PBSC inoculum. [13] [14] [15] [16] [17] We conducted a retrospective analysis of related-donor allogeneic transplants to determine whether patients receiving PBSC transplantation were more likely to experience hemolytic complications of ABO-incompatible transplantation than were patients undergoing bone marrow transplantation. We were unable to demonstrate evidence of hemolysis after use of either source of HSC.
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Materials and methods
Patients
This is a retrospective study of a sequential series of 158 allogeneic hematopoietic stem cell transplants from ABOincompatible, related donors between January 1995 and September 1998. Patients selected for the review received cells from HLA-identical but ABO-incompatible family donors. The decision to use marrow or PBSC as the source of HSC was determined by protocol eligibility or by recommendation of the medical care team caring for the patient. Problem-oriented monthly summaries of the transplant course and hospital admission and discharge summaries were reviewed for reports of hemolysis for all patients. Charts were also reviewed for laboratory evidence of hemolysis or increased red cell transfusion requirements. Patients were enrolled in treatment regimens approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center and informed consent for HSC donation and transplantation was obtained for all patients and donors.
Conditioning regimen and GVHD prophylaxis
These patients received predominantly busulfan or TBIbased conditioning regimens. Regimens used included busulfan (Bu) 1 mg/kg p.o. four times a day ϫ 4 days followed by cyclophosphamide (Cy) 60 mg/kg i.v. daily ϫ 2 days (BuCy, n ϭ 67 including two patients who also received anti-thymocyte globulin); and Cy followed by total body irradiation (TBI) of 10.5-15.7 Gy over 4 days given in various schedules (Cy TBI, n ϭ 48). Other regimens included BuCy (n ϭ 9) or CyTBI (n ϭ 5) after administration of I131 labeled anti-CD45 monoclonal antibody, 18 BuCy with 9 Gy of TBI with lung and liver shielding (n ϭ 4), Bu 0.44 mg/kg p.o. four times a day ϫ 4 days with TBI 12 Gy administered in six fractions over 3 days (n ϭ 10). Patients treated for aplastic anemia were conditioned with Cy 50 mg/kg i.v. daily ϫ 4 days in combination with ATG (n ϭ 7). The remaining nine patients received a variety of other myeloablative conditioning regimens appropriate to the disease being treated and the clinical status of the patient.
Most (n ϭ 150) patients received GVHD prophylaxis consisting of cyclosporine 1.5 mg/kg i.v. twice a day starting on day Ϫ1 followed by 15 mg/m 2 of methotrexate i.v. on day 1 and 10 mg/m 2 on days 3, 6 and 11 (CSPMTX) as previously described. 19 Administration of MTX was delayed until 24 h after completion of all infusions for those patients who received more than one PBSC infusion. Two patients received methotrexate alone at the doses described above, but continued weekly until day 49 (MTX). Two patients received CSPMTX with prednisone and one patient received cyclosporine in combination with trimetrexate. 20, 21 The remaining three patients were treated with CSP and prednisone. 20 Day 0 was defined as the day of HSC infusion. For patients receiving PBSC on more than one day, day 0 was the first day of cell infusion. None of the HSC components were depleted of T cells as prophylaxis against GVHD.
HSC component harvesting and processing
Bone marrow cells were harvested from the posterior iliac crest of the donor as previously described. 22 PBSC were collected by apheresis from filgrastim-treated donors, also as previously described. 23 The harvest procedures were not modified because of ABO incompatibility between donor and recipient.
Major ABO-incompatible bone marrow components were depleted of red blood cells by centrifugation using a COBE Spectra apheresis device (COBE BCT, Lakewood, CO, USA) if the recipient's isoagglutinin titers exceeded 1:16 (IgM and/or IgG). 24 Plasmapheresis to reduce recipient isoagglutinin titers was not routinely performed for these patients. One recipient of a major ABO-incompatible marrow received a red cell-depleted bone marrow component after undergoing plasmapheresis; a second with aplastic anemia was treated with plasmapheresis in order to avoid the risk of cell loss from the marrow component as a consequence of red cell depletion. Minor ABO-incompatible marrow components were plasma-depleted by centrifugation if donor isoagglutinin titers (IgG and/or IgM) exceeded 1:128. Normosol-R was added to replace the volume of plasma removed. For bidirectional ABO-incompatible bone marrow transplants, red blood cell or plasma depletion or both was performed, using the criteria described above for major or minor ABOincompatible transplants. Red cell depletion using this apheresis technique also resulted in plasma depletion for bidirectional incompatible transplants. PBSC components were not manipulated by either red cell or plasma depletion, although the red cell content of the PBSC component was assessed before infusion. All PBSC and RBC-depleted components contained less than 15 ml of red blood cells, with most containing less than 8 ml.
Transfusion support
Patients were transfused with red blood cells to maintain a hematocrit greater than 26% and with platelets to maintain a platelet count of greater than 20 ϫ 10 9 /l while hospitalized, or greater than 10 ϫ 10 9 /l during subsequent outpatient care. The ABO type of blood components transfused after transplantation was defined by the blood groups of the HSC donors and recipients. Patients undergoing major or bidirectional ABO-incompatible transplants received group O red cells although group AB recipients of cells from group A or B donors could receive donor-type red blood cells. This transfusion support was maintained until recipient isoagglutinins directed against the donor ABO type were undetectable for 2 consecutive weeks. Donor-type red cells were then infused as needed. Patients undergoing minor ABO-incompatible transplants were also transfused with group O red blood cells although group A or B recipients of HSC from group AB donors could receive recipient ABO-type red cells. To allow comparison of patients of differing blood volumes, the number of units of red blood cells infused each week after transplantation (starting on day 0) was adjusted by dividing by the calculated body surface area (BSA) of the patient. The preferred ABO type of platelets was that of the donor for major ABO-incompatible transplants and of the recipient for minor ABO-incompatible transplants. Bidirectional ABO-incompatible recipients received plasma-depleted platelet components of donor ABO type. Plasma-depleted platelet components of other ABO types could be infused for these patients if a component of the desired type was not available. All red blood cell and platelet components were irradiated to 2500 cGy.
Time to granulocyte engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count greater than 0.5 ϫ 10 9 /l; time to platelet engraftment was defined as the first of 7 consecutive days with a platelet count greater than 20 ϫ 10 9 /l without transfusion support.
Laboratory testing
Routine laboratory tests after transplantation included daily complete blood counts (CBC). A chemistry profile including bilirubin was obtained three times per week or more frequently as needed for patient management. Lactate dehydrogenase (LDH) was not routinely measured.
Isoagglutinin titers for patients receiving major ABOincompatible transplantation were examined pre-transplant and after transplantation until the titers were undetectable for 2 consecutive weeks or until discharge from Seattle. Titers were classified by ABO-antigen (anti-A, anti-B) and antibody (IgM, IgG) types.
Direct anti-globulin testing (DAT) for red cell antibodies was routinely performed before but not after transplantation. We obtained this test prospectively in a separate group of 22 patients undergoing minor or bidirectional ABO-incompatible marrow (n ϭ 17) or PBSC (n ϭ 5) transplantation from related or unrelated donors on days 6, 8, 10 and 12 after transplantation. These patients were not included in the sequential series of patients reviewed in this report. All 22 patients in this group received CSPMTX as GVHD prophylaxis after transplantation. The specificity of the antibody using eluates from the red blood cells was determined for some of these patients with positive testing. The direct anti-globulin test and subsequent preparation and analysis of red cell eluates used standard blood banking techniques.
Statistical analysis
This is a retrospective study of hemolysis after transplantation for recipients of PBSC or bone marrow as a source of HSC. Patient characteristics, as well as characteristics of the marrow and PBSC harvest procedures are described using appropriate summary statistics such as median values and ranges. Examinations of the differences between patient groups were performed using Student's t-test for independent samples. Examinations of the differences in median transfusion requirements between patient groups were performed using Kruskal-Wallis analysis of variance by ranks test. Differences in times to achieve endpoints of engraftment were determined by calculating the log-rank statistic with censuring of patients who did not achieve the endpoint.
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Results
A total of 158 patients received marrow or PBSC components from HLA-identical but ABO-incompatible sibling donors. Patient and donor demographics and the treatment regimens used are shown in Table 1 . Incompatibility for Rhesus (Rh) antigens was not used in determining transfusion support after transplantation, except for female patients expected to maintain fertility after transplantation. Although 12 of the recipients were Rh-negative recipients of HSC components from Rh-positive donors and 15 Rhpositive recipients received components from Rh-negative donors, antibodies directed against Rh antigens were not detected in any of the donors before HSC collection or any of the recipients before or after transplantation. None of the patients or donors had evidence of immunization to other red cell antigens at the time of transplantation.
Engraftment
The median times to achieve endpoints of engraftment are shown in Table 2 . For all patients studied, patients receiving PBSC components achieved granulocyte engraftment and platelet engraftment significantly faster than BM recipients (P Ͻ 0.001 for analysis of each endpoint of engraftment). For patients grouped by type of ABO mismatch, engraftment was more rapid for both endpoints of analysis for recipients of PBSC regardless of the direction of ABO mismatch (P Ͻ 0.001 for analyses of granulocyte engraftment, P Ͻ 0.005 for analyses of platelet engraftment; bidirectional ABO-incompatibility recipients were excluded from these analyses because of limited numbers of patients in each group). When grouped by stem cell source (marrow or PBSC) but classified by type of ABO mismatch (bidirectional ABO-incompatibility recipients excluded), granulocyte or platelet engraftment times did not differ within the groups transplanted with either PBSC or marrow (P Ͼ 0.1 for all analyses), which indicates that the source of HSC, not the ABO mismatch, affected the kinetics of granulocyte and platelet recovery after transplantation.
Hemolysis
A clinical diagnosis of severe hemolysis resulting from the infusion of ABO-incompatible HSC and requiring specific medical intervention was not made for any patient during the first 28 days after transplantation. Chart review of monthly summaries by attending physicians was conducted, and we discovered six (one recipient of major ABO-incompatible PBSC, three recipients of major ABO-incompatible marrow, one recipient of bidirectional-incompatible marrow, and one recipient of minor-incompatible marrow) patients for whom hemolysis was speculated as a possible cause of elevated bilirubin after transplantation. An elevation of LDH was not documented for any of these six patients and only one patient (recipient of a minor-incompatible marrow component) experienced a bilirubin rise more than twice the upper limit of normal. None of these six patients received red cell transfusion support more than 1 standard deviation above the mean. 
a Shown is median (range). b Details regarding diagnosis, conditioning regimen, and GVHD prophylaxis are described in Methods.
c Includes one patient who underwent plasmapheresis to reduce isoagglutinins directed against donor red blood cells. Diagnoses include: ALL ϭ acute lymphocytic leukemia; AML ϭ acute myelogenous leukemia; CML ϭ chronic myelogenous leukemia; MDS ϭ myelodysplasia. Other diagnoses include: aplastic anemia, chronic lymphocytic leukemia, chronic myelomonocytic leukemia, Fanconi's anemia, hypereosinophilic syndrome, multiple myeloma, neuroblastoma, paroxysmal nocturnal hemoglobulinuria, thalassemia, and Hodgkin's disease.
LDH values were not routinely obtained after transplantation, but we identified three patients who demonstrated LDH values more than twice the upper limit of normal: one recipient of minor-incompatible marrow was diagnosed with microangiopathic hemolytic anemia attributed to cyclosporine 20 days after transplantation; one recipient of major-incompatible PBSC was diagnosed with diffuse alveolar damage 18 days after transplantation; and one recipient of major-incompatible marrow was diagnosed with sepsis and hepatic veno-occlusive disease 11 days after transplantation. Hemolysis resulting from ABOincompatible transplantation was not documented for any of these three patients.
Red blood cell transfusion requirements
We examined the red blood cell transfusion requirements during the 4 weeks after transplantation. To account for differences in patient size and for loss of patients because of mortality occurring during this time, red cell transfusions were adjusted to number of units per m 2 body surface area (BSA) per day (Table 3) . Total units transfused per m 2 BSA for the entire transplant course were also calculated. Recipients of major ABO-incompatible transplants required, on average, more transfusions than those receiving minor ABO-incompatible transplants, which is consistent with the previously described suppressive effects of recipient isoagglutinins on red cell hematopoiesis after transplantation. 7, 8 The lower transfusion requirements for recipients of minor ABO-incompatible marrow components during the first week after transplantation is consistent with the infusion of a larger quantity of red blood cells contained in these components, compared to bone marrow components that had been red cell depleted by apheresis technology, which all but three of the major ABO-incompatible marrow recipients received (median, 0.15 vs 0.00 U/m 2 /day; P ϭ 0.0002). The lack of differences between recipients of major and minor ABO-incompatible transplants in red cell transfusion requirements during the second week after transplantation (days [8] [9] [10] [11] [12] [13] [14] for either recipients of marrow (median, 0.18 vs 0.21 U/m 2 /day; P ϭ 0.47 ) or PBSC (median, 0.16 vs 0.17 U/m 2 /day; P ϭ 0.21) infusions is also evidence indicating that severe hemolysis did not occur as a result of donor isoagglutinins produced by 'passenger lymphocytes' in the HSC component.
Bilirubin
Elevation of total bilirubin was common during the first 21 days after transplantation, with abnormal values (Ͼ1.8 mg/dl) experienced by 113 of these patients ( Table 4 ). The average maximum for patients receiving marrow components was 5.9 Ϯ 7.4; for PBSC recipients, 4.1 Ϯ 7.1 (P ϭ 0.16). When grouped by type of ABO mismatch (excluding Bone Marrow Transplantation bidirectional mismatch recipients) and classified by source of HSC, recipients of major ABO-incompatible PBSC components tended to a lower maximum bilirubin (P ϭ 0.06) than recipients of bone marrow, which is probably not explained by hemolysis of marrow red blood cells for the three marrow recipients who received components that were not red cell depleted before infusion (average maximum bilirubin for these patients was 3.4 mg/dl). The average maximum bilirubin for recipients of minor ABOincompatible marrow or PBSC components did not differ (P ϭ 0.82). When grouped by source of HSC but classified by type of mismatch (excluding bidirectional mismatch recipients), the maximum bilirubin after infusion of major compared to minor ABO-incompatible components did not differ for marrow recipients (P ϭ 0.61) or for PBSC recipients (P ϭ 0.13).
Isoagglutinin titers
Isoagglutinin titers directed against the ABO type of the donor were measured on a weekly basis for recipients of major ABO-incompatible HSC components. Both PBSC and marrow recipients showed an exponential fall in both IgM and IgG titers after transplantation (Figure 1a-d) . A total of 15 patients had titers that became undetectable for 2 or more consecutive weeks: six were recipients of marrow and the remaining nine were recipients of PBSC components. For marrow recipients, the second consecutive undetectable titer occurred at a median time of 7.5 weeks (range, 6-9 weeks). The median for PBSC recipients was seven weeks (range, 4-9 weeks).
While most patient titers decreased after transplantation, two patients exhibited transient 16-to 4096-fold rises in titers. Both patients received marrow components and CSPMTX for GVHD prophylaxis. Neither of these patients experienced any adverse events from these rises in titers, which resolved over the ensuing weeks.
Prospective DAT testing
DAT testing to detect isoagglutinins directed against recipient isoantigens was not routinely performed. This testing was obtained prospectively for a small series of patients, mostly recipients of HSC components from unrelated donors ( Table 5) . Eight of these patients demonstrated positive DAT testing during the second week after transplantation when delayed hemolysis mediated by 'passenger lymphocytes' is most likely to occur. These reactions were weak, being rated by the laboratory technologist as 'weakly positive' or '1ϩ'. However, the transient presence of antibodies directed against recipient isoagglutinins was found for three patients. Whether these tests resulted from 'passenger lymphocytes' or passive transfusion (two of these three received plasma-replete marrow infusions) cannot be determined. None of these patients experienced severe hemolysis during this time.
Discussion
We were unable to demonstrate an adverse effect from hemolysis during the first 21 days after transplantation resulting from choice of HSC source for transplantation between HLA-compatible but ABO-incompatible siblings. Shown are results of DAT for 22 patients transplanted with minor or bidirectional ABO-incompatible marrow or PBSC components. The eight patients shown all experienced positive tests using polyspecific reagents. Further testing was performed to determine if IgG or complement factors were present on the patients' red blood cells. All tested were reported as either 'weakly positive' or '1ϩ.' Elutriation and speciation of the antibody was performed for some patients. ND ϭ not done; Neg ϭ negative (no antibodies detected); Pos ϭ positive (antibodies directed against recipient ABO antigens detected).
None of these patients suffered clinically evident hemolysis, especially of the fulminant severity previously reported by others after minor ABO-incompatible HSC transplantation. [10] [11] [12] [13] [14] [15] [16] [17] Indirect measurements of hemolysis such as rise in bilirubin after transplantation, shown by others to be affected by ABO-incompatible transplantation, 25 did not differ between groups defined by source of HSC or direction of ABO incompatibility. The only patient with a markedly elevated LDH (Ͼ4ϫ normal) showed schistocytes in the peripheral blood smear consistent with extravascular hemolysis occurring 20 days after transplantation. 26 As expected, the recipients of PBSC achieved granulocyte and platelet engraftment faster than did recipients of marrow. We did not test time to reticulocyte recovery, but the differences in red blood cell transfusion requirements that were detected can be explained by differences in the red blood cell content of the HSC component (minor ABO-incompatible marrow components that are infused without red cell depletion contain considerably more red cells than do marrow components processed by apheresis technology or PBSC components) and by the more rapid engraftment kinetics of PBSC recipients. Although prospective testing showed positive DAT tests for eight of 22 patients, all eight received marrow suggesting that 'passenger lymphocytes' in the PBSC inoculum are not a frequent cause of hemolysis after transplantation. We did not detect a difference in the resolution of recipient anti-donor ABO group isoagglutin titers after major ABOincompatible transplantation. Resolution of these isoagglutinins is hastened by the acute GVHD, 27 which develops in similar proportions of patients transplanted with either source of HSC. 28 
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Transplantation of ABO-incompatible HSC components has been associated with a number of complications that differ according to the direction of the incompatibility. The immediate risk of hemolysis resulting from the infusion of bone marrow containing a large quantity of incompatible red cells can be avoided by removal of the incompatible red cells using any of a variety of techniques. If the HSC inoculum contains few red cells or donor isoagglutinin titers are low, the risk of hemolysis occurring during infusion of the inoculum is minimal and poses little risk to the recipient. PBSC collected and marrow components processed by apheresis technology usually contain less than 10-15 ml of red cells and present little risk of clinically severe hemolysis on infusion. The other consequence of major ABO-incompatible transplantation is possible delay in recovery of red cells until loss of isoagglutinins directed against donor red cell antigens. Pure red cell aplasia lasting months to years can occur in this setting. [7] [8] [9] Expression of ABO antigens occurs about the time of hemoglobinization. 29 It is unlikely that major elevations in bilirubin or LDH are related to intra-medullary hemolysis in this setting.
Massive hemolysis occurring as a delayed consequence of infusion of viable donor lymphocytes ('passenger lymphocytes') may result in patient death after minor ABOincompatible transplantation. The incidence of and risk factors for delayed hemolysis for recipients of minor ABOincompatible cells are not defined. Most transplant programs will avoid transfusion of recipient-type red blood cells after transplantation. Transfusion of group O cells will dilute the quantity of recipient red cells and some transplant programs use red cell exchange to further reduce the quan-Bone Marrow Transplantation tity of incompatible red cells in the recipient. 11 Gajewski et al 11 suggested that post-transplant immunosuppressive regimens containing methotrexate would reduce the risk of delayed hemolysis mediated by viable lymphocytes contained within the HSC inoculum, and this may explain the suggestion that the risk of hemolysis is higher after transplantation of T-depleted marrows without the use of antimetabolites. 30 The case reports of delayed hemolysis after PBSC transplantation involved patients who received regimens without methotrexate or for whom some doses of this drug were withheld.
14-17 Most of our patients received two drug prophylactic regimens after transplantation that included methotrexate. Methotrexate (and other agents such as mycophenylate mofitil) is an anti-proliferative agent that may suppress the proliferation of donor lymphocytes carried in the HSC inoculum. 31 However, the incidence of hemolysis after transplantation in the absence of methotrexate is also not defined. Not all patients will experience delayed hemolysis and the risk factors could include both donor and recipient factors.
Although it is not evident from our data that the use of PBSC as a source of HSC increases the risk of delayed hemolysis after minor ABO-incompatible transplantation, the published case reports of hemolysis suggest that this should be considered if different post-transplant immunosuppressive regimens are to be used. Recipients of minor ABO-incompatible PBSC transplants treated with single drug immunosuppressive regimens after transplantation may benefit from vigilant monitoring for evidence of hemolysis during the second week after transplantation when delayed hemolysis is likely to occur. Certainly, infusion of recipient-type red cells should be avoided after transplantation for all patients receiving minor incompatible marrow or PBSC transplants to lessen the quantity of red blood cells that could be hemolyzed if donor isoagglutinins are produced.
